Clinical trial NCT01842503: Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent
Official title: A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Alcohol Dependence
Keywords: alcohol dependence
cue reactivity
alcohol self administration
Lead sponsor: Laboratorio Farmaceutico Ct S.r.l.
Sponsor class: INDUSTRY
Collaborators: name: Voisin Consulting, Inc.
name: Latis S.r.l.
name: Quotient Bioresearch
First posted: 2013-04-29
Enrollment: 25
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Examination of the effect of GET 73 on alcohol pharmacokinetics and pharmacodynamics (intoxication and sedation)and safety profile in alcohol-dependent individuals.To evaluate whether GET 73, as compared to placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink during the cue reactivity session and results in lower quantity of alcohol consumed during an alcohol self-administration session.


Eligibility criteria: Inclusion Criteria:

* male or female subjects, between 21 and 65 years old (inclusive);
* participants must meet criteria for current Diagnostic and Statistical Manual (DSM-IV)diagnosis of alcohol dependence,supported by the structured clinical interview for DSM-IV Axis I Disorders Patient Edition;
* participants must meet criteria for heavy drinking, defined as averaging

  * 4 drinks/day for women and ≥5 drinks/day for men during a 30-day period within the 90 days prior to screening evaluation;
* participants must be in good health as confirmed by medical history, physical examination, ECG, lab tests;
* females must be postmenopausal for at least one year or surgically sterile. Otherwise, females will be excluded (even if they are using any kind of birth control). Proof (medical records, certification from an medical doctor) of surgical sterility will be required. Certification of postmenopausal for at least 1 year and postmenopausal levels of FSH will also be required to be into the study;
* participants must be willing to take oral medication and adhere to the study procedures;
* participants must give their consent to enter the study by signing the informed consent form.

Exclusion Criteria:

* individuals seeking treatment for alcohol dependence;
* positive urine drug screen at baseline for positive drug screen for the following: opioids, benzodiazepines, cocaine, methamphetamine or any other stimulants. A urine drug screen may be repeated once and must test negative before randomization;
* individuals diagnosed with a current substance dependence, other than alcohol or nicotine;
* meet DSM-IV Axis I criteria for a lifetime diagnosis of schizophrenia, bipolar disorder, or other psychoses;
* Subjects taking any psychoactive medication that in the opinion of the subjects primary care physician, cannot be discontinued at least 14 days prior to being randomized;
* an active illness within the past 6 months of Visit 1 that meet the DSM-IV criteria for a diagnosis of Major Depressive Disorder or Anxiety Disorder;
* subjects with a history of suicide attempts and/or at risk for suicide will be excluded, based on the Structured Clinical Interview Disorders assessment and on the Investigators' evaluation;
* clinically significant medical abnormalities (i.e., unstable hypertension, clinically significant abnormal ECG, bilirubin \> 150% of the upper normal limit, alanine aminotransferase or aspartate aminotransferase elevations \>300% the upper normal limit, estimated creatinine clearance ≤ 60 dl/min);
* current use of any medications prescribed to reduce alcohol use e.g. naltrexone, acamprosate, disulfiram or topiramate;
* concomitant use of cytochromeP450 2C19 substrates; assumption of cytochromeP450 2C19 and cytochromeP450 3A4 inhibitors or inducers in the 14 days before dosing;
* individuals with a reasonable expectation of being institutionalized during the course of the trial;
* participants who have significant alcohol withdrawal symptoms, defined as a Clinical Institute Withdrawal Assessment \>10;
* history of seizures (e.g. epilepsy), including alcohol-related seizures;
* history of delirium tremens;
* subjects who have participated in any behavioral and/or pharmacological study within the past 30 days;
* history of delirium tremens.

Primary outcomes:
measure: changes in area under the plasma concentration of alcohol versus time curve (AUC), after administration of GET 73 or placebo
timeFrame: blood samples are drawn on day 2 and day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations
measure: Changes in pleasurable and negative effects of alcohol intoxication and sedation, measured by the Biphasic Alcohol Effects Scales (BAES),during the Alcohol Self-Administration (ASA) session, when taking GET 73 compared to placebo.
timeFrame: The BAES will be administered, at Day 2 and Day 12, eight times after the priming drink is presented during the ASA.
measure: Changes in reaction time, measured by Conners's Continuous Performance Task (CPT),when taking GET 73 compared to placebo
timeFrame: CPT will be assessed at Day 2 and Day 12
measure: Changes in cognitive performance, measured by Digit Symbol Substitution Test (DSST), when taking GET 73 compared to placebo
timeFrame: DSST will be assessed at Day 2 and Day 12
measure: Frequency of adverse events (AEs) occured after placebo or GET 73 administration
timeFrame: up to 20-27 days
measure: Changes in cue reactivity (CR) responses to alcohol cues, in terms of urge to drink, as measured by the Alcohol Urge Questionnaire (AUQ), when taking GET 73 compared to placebo.
timeFrame: At Day 3 and Day 13 during the two treatment phases
measure: Changes in CR responses to alcohol cues, in terms of psychophysiological responses,heart rate,mean arterial pressure and salivation changes during the CR session.
timeFrame: At Day 3 and Day 13 during the two treatment phases
measure: Changes in attention to the sight and smell of cues, as measured by Alcohol Attention Scale (AAS), during the CR.
timeFrame: This endpoint will be measured twice in each CR session (Day 3 and Day 13) through the AAS.
measure: Effects of GET 73 on the amount of alcohol consumed during the ASA. The maximum quantity of alcohol will be taken, to have a measure directly comparable to AUQ results
timeFrame: At Day 3 and Day 13 during the two treatment phases
measure: Changes in peak plasma concentration (Cmax) of alcohol after administration of GET 73 or placebo
timeFrame: blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations
measure: Changes in time to peak plasma level (Tmax) of alcohol after administration of GET 73 or placebo
timeFrame: blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations
measure: Changes in half-life of alcohol after administration of GET 73 or placebo
timeFrame: blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations
measure: Characteristics of adverse events (AEs) occured after placebo or GET 73 administration
timeFrame: up to 20-27 days
Secondary outcomes:
Other outcomes:
Locations:
city: Providence
country: United States
facility: Roger Williams Medical Center
state: Rhode Island
Study officials:
affiliation: Roger Williams Medical Center
name: Robert M. Swift, M.D., R.Ph.
role: PRINCIPAL_INVESTIGATOR
References: